- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Evaluate Acquires J+D Forecasting
Both companies are now under the Norstella umbrella.
Evaluate announced the acquisition of J+D Forecasting, a provider of forecasting solutions focused on the pharmaceutical and life sciences industry.
The move will bring J+D under the Norstella umbrella, the parent company of Evaluate. The parent company also includes Citeline, MMIT, Panalgo, and The Dedham Group. Norstella works to bring therapies to patients and provide insights to pharmaceutical companies during the drug development life cycle.
As part of Norstella, Evaluate provides companies in the life sciences industry with data, insights, and intelligence related to high-value investments for treatments.
In a press release sent to Pharmaceutical Executive, Norstella CEO Mike Gallup said, “We are delighted to welcome the J+D Forecasting team to the Norstella family. Their expertise in developing bespoke forecasting models and innovative, intuitive solutions will provide our customers with an even wider breadth of expertise and cutting-edge insight. The addition of these capabilities significantly boosts our ability to help achieve our mission of smoothing the path of life-saving therapies from pipeline to patient.”
According to the press release, Norstella plans to implement J+D’s forecasting models to improve its forecasting portfolio. The company also plans on using generative AI programs to analyze the data and create comprehensive solutions.
In the same press release, J+D CEO and founder David James said, “The need for high quality forecasting to support decision making in the pharmaceutical and biotech space has never been higher. Bringing together two of the most respected forecasting providers in the industry provides huge opportunities for our customers and I am looking forward to working with the Evaluate team and Norstella to bring innovative solutions to the market.”
In the press release, Evaluate states that this acquisition will provide them with the ability to provide better forecasts related to market size, growth in key indications, and demand for new technologies.
Source
(Jan. 10, 2024); Norstella; Evaluate Announces Acquisition of J+D Forecasting; press release
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
